EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol

Shoa L Clarke iD, Rose D L Huang, Austin T Hilliard, Michael G Levin, Disha Sharma, Blake Thomson, Julie Lynch iD, Philip S Tsao, J Michael Gaziano, Themistocles L Assimes, VA Million Veteran Program

European Journal of Preventive Cardiology · 2025

DOI: 10.1093/eurjpc/zwae271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Preventive Cardiology, 2025. Verfasst von Shoa L Clarke und 10 weiteren Autor:innen. Beteiligte Einrichtung: VA Palo Alto Healthcare System, 3801 Miranda Avenue, Palo Alto, CA, 94304, USA. Hauptthemen laut MEDLINE: Cholesterol, LDL, Coronary Artery Disease, Lipoprotein(a), Plaque, Atherosclerotic. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Million Veteran Program, Department of Veterans Affairs Office of Research and Development, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Elevated lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease, but the mechanisms of risk are debated. Studies have found inconsistent associations between Lp(a) and measurements of atherosclerosis. We aimed to assess the relationship between Lp(a), low-density lipoprotein cholesterol (LDL-C), and coronary artery plaque severity. Methods and results The study population consisted of participants of the Million Veteran Program who have undergone an invasive angiogram. The primary exposure was genetically predicted Lp(a) estimated by a polygenic score. Genetically predicted LDL-C was also assessed for comparison. The primary outcome was coronary artery plaque severity categorized as normal, non-obstructive disease, one-vessel disease, two-vessel disease, and three-vessel or left main disease. Among 18 927 adults of genetically inferred European ancestry and 4039 adults of genetically inferred African ancestry, we observed consistent associations between genetically predicted Lp(a) and obstructive coronary plaque, with effect sizes trending upward for increasingly severe categories of disease. Associations were independent of risk factors, clinically measured LDL-C and genetically predicted LDL-C. However, we did not find strong or consistent evidence for an association between genetically predicted Lp(a) and risk for non-obstructive plaque.

Conclusion

Genetically predicted Lp(a) is positively associated with coronary plaque severity independent of LDL-C, consistent with Lp(a) promoting atherogenesis. However, the effects of Lp(a) may be greater for progression of plaque to obstructive disease than for the initial development of non-obstructive plaque. A limitation of this study is that Lp(a) was estimated using genetic markers and could not be directly assayed nor could apo(a) isoform size.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLCoronary Artery DiseaseLipoprotein(a)Plaque, AtheroscleroticAgedFemaleHumansMaleMiddle AgedBiomarkersCoronary AngiographyGenetic Predisposition to DiseasePhenotypeRisk AssessmentRisk FactorsSeverity of Illness IndexUnited StatesWhiteBlack or African American

Stichwörter der Autor:innen

AtherosclerosisCoronary artery diseaseLDL-CLipoprotein(a)Polygenic score

Substanzen

BiomarkersCholesterol, LDLLipoprotein(a)LPA protein, human

Autor:innen und Institutionen

  • VA Palo Alto Healthcare System, 3801 Miranda Avenue, Palo Alto, CA, 94304, USA.
  • Department of Medicine, Stanford Prevention Research Center, Stanford University School of Medicine, 300 Pasteur Drive, Palo Alto, CA, 94304, USA.
  • Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.
  • Corporal Michael J. Crescenz VA Medical Center, 3900 Woodland Avenue, Philadelphia, PA, 19104, USA.
  • Department of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

ORCID-Profile: Shoa L Clarke, Julie Lynch

Förderung

  • Million Veteran Program
  • Department of Veterans Affairs Office of Research and Development
  • NCATS NIH HHS
  • BLRD VA
  • Department of Veteran Affairs or the United States Government

Zitieren

APA

Clarke, S. L., Huang, R. D. L., Hilliard, A. T., Levin, M. G., Sharma, D., Thomson, B., Lynch, J., Tsao, P. S., Gaziano, J. M., Assimes, T. L., & VA Million Veteran Program (2025). Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwae271

Vancouver

Clarke SL, Huang RDL, Hilliard AT, Levin MG, Sharma D, Thomson B, et al. Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol. European Journal of Preventive Cardiology. 2025. doi:10.1093/eurjpc/zwae271

BibTeX
@article{Clarke2025,
  author = {Clarke, Shoa L and Huang, Rose D L and Hilliard, Austin T and Levin, Michael G and Sharma, Disha and Thomson, Blake and Lynch, Julie and Tsao, Philip S and Gaziano, J Michael and Assimes, Themistocles L and VA Million Veteran Program, VA Million Veteran Program},
  title = {Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol},
  journal = {European Journal of Preventive Cardiology},
  year = {2025},
  doi = {10.1093/eurjpc/zwae271}
}
Kostenlos starten →